Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4121186 | 0.87 | ACHE (0.44) | ACHEBCHE | |
| SCHEMBL4125615 | 0.86 | ACHE (0.40) | ACHEBCHE | |
| SCHEMBL4121503 | 0.85 | ACHE (0.56) | ACHEBCHE | |
| SCHEMBL4116955 | 0.85 | ACHE (0.37) | ACHEBCHETLR9TLR8TLR7 | |
| SCHEMBL4115142 | 0.84 | ACHE (0.39) | ACHEBCHETLR9TLR8TLR7 | |
| Hydrochloric Acid SCHEMBL4120172 | 0.84 | ACHE (0.55) | ACHEBCHE | |
| SCHEMBL4115043 | 0.84 | GRM2 (0.38) | ACHETLR9TLR8TLR7 | |
| SCHEMBL4114643 | 0.83 | SLC6A4 (0.41) | ACHEBCHETLR9TLR8TLR7 | |
| SCHEMBL13966088 | 0.83 | ACHE (0.36) | ACHEBCHETLR9TLR8TLR7 | |
| SCHEMBL4133483 | 0.83 | GPR119 (0.38) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | ACHE 3716/4885BCHE 2215/4885TLR9 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.